Healthy adult
Conditions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy males and females from 20 to 64 years of age 2. Subjects whose BMI is 23kg/m2 or more and less than 30kg/m2 3. The average blood pressure, triglycerides, HDL-cholesterol, and blood glucose of the people starting intake should be within the reference range for each item
Exclusion criteria
Exclusion criteria: 1. Subjects who regularly ingest food, health food or medicine rich in lactic acid bacteria or natto bacteria 2. Subjects who regularly ingest health food or medicine that affects body fat and lipid metabolism 3. Subjects who are judged to be unsuitable for research from the results of the screening test 4. Subjects who may develop allergies related to the study 5. Subjects who exercise excessively 6. Subjects who are on a diet at the time of the screening test 7. Subjects who have a disease requiring regular administration, or who have a history of severe disease 8. Subjects whose physical measurement values, blood pressure values, and clinical inspection values are significantly outside the reference range before starting intake 9. Subjects who have or have a history of a severe disease 10. Subjects who drink a lot 11. Subjects who are judged to be unsuitable for the study based on the results of lifestyle questionnaires 12. Subjects who donated blood within one month before the study 13. Subjects who have participated in other clinical study within one month before the study or plan to participate in other clinical study after informed consent to the study 14. Subjects who are pregnant or breastfeeding, or plan to do so during this study 15. Subjects judged as unsuitable for the study by a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal fat | — |
Secondary
| Measure | Time frame |
|---|---|
| waist circumference, hip circumference, waist circumference / hip circumference, body weight, BMI, body fat percentage, blood index | — |
Countries
Japan
Contacts
EP Mediate Co., Ltd. Foods Department, Trial Planning Section 2